Who Pays My Doctor?

Healthcare provider profile · identity verified

Scott A. Young, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · LOUISVILLE, KY · NPI 1104018977

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Scott A. Young, M.D. received $457.73 in general payments during 2025 across 14 reported records.

GlaxoSmithKline, LLC. accounted for 29.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 10 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$457.73

14 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $136.2329.8%22025
Bayer Healthcare Pharmaceuticals Inc. Unresolved — no canonical attribution shown $125.4127.4%12025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $37.798.3%22025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $37.658.2%22025
Exact Sciences Corporation Unresolved — no canonical attribution shown $36.888.1%22025
Amgen Inc. Unresolved — no canonical attribution shown $35.457.7%22025
Azurity Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $32.357.1%22025
Esperion Therapeutics, Inc. Unresolved — no canonical attribution shown $15.973.5%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$457.7314

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
AREXVY
Normalized: arexvy		 Biological GlaxoSmithKline, LLC. $136.23 2 2025
Source payment records
Kerendia
Normalized: kerendia		 Drug Bayer Healthcare Pharmaceuticals Inc. $125.41 1 2025
Source payment records
LEQVIO
Normalized: leqvio		 Drug Novartis Pharmaceuticals Corporation $37.79 2 2025
Source payment records
TRINTELLIX
Normalized: trintellix		 Drug Takeda Pharmaceuticals U.S.A., Inc. $37.65 2 2025
Source payment records
Cologuard Collection Kit
Normalized: cologuard collection kit		 Device Exact Sciences Corporation $36.88 2 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $35.45 2 2025
Source payment records
REPATHA
Normalized: repatha		 Biological Amgen Inc. $35.45 2 2025
Source payment records
EDARBI
Normalized: edarbi		 Drug Azurity Pharmaceuticals, Inc. $32.35 2 2025
Source payment records
TRELEGY ELLIPTA
Normalized: trelegy ellipta		 Drug GlaxoSmithKline, LLC. $16.04 1 2025
Source payment records
NEXLETOL
Normalized: nexletol		 Drug Esperion Therapeutics, Inc. $15.97 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Rosuvastatin CalciumRosuvastatin Calcium842235
Atorvastatin CalciumAtorvastatin Calcium409106
Amlodipine BesylateAmlodipine Besylate385112
Levothyroxine SodiumLevothyroxine Sodium27869
IrbesartanIrbesartan25570
LisinoprilLisinopril22364
Metoprolol SuccinateMetoprolol Succinate17751
OmeprazoleOmeprazole13438
HydrochlorothiazideHydrochlorothiazide12440
Zolpidem TartrateZolpidem Tartrate11038
OzempicSemaglutide10417
Metformin HclMetformin Hcl10328
AllopurinolAllopurinol10026
MeloxicamMeloxicam9027
Pantoprazole SodiumPantoprazole Sodium8427
Tamsulosin HclTamsulosin Hcl8226
Sertraline HclSertraline Hcl8024
Potassium ChloridePotassium Chloride7625
Losartan PotassiumLosartan Potassium7523
Bupropion XlBupropion Hcl7225
EzetimibeEzetimibe7121
EliquisApixaban6418
AlprazolamAlprazolam6218
AtenololAtenolol5715
Metoprolol TartrateMetoprolol Tartrate5417
AzithromycinAzithromycin5346
Candesartan CilexetilCandesartan Cilexetil5213
FurosemideFurosemide4917
Clonidine HclClonidine Hcl4615
Olmesartan MedoxomilOlmesartan Medoxomil4616
Fluoxetine HclFluoxetine Hcl4412
Tramadol HclTramadol Hcl43suppressed
Fluticasone PropionateFluticasone Propionate4119
ClopidogrelClopidogrel Bisulfate4014
JardianceEmpagliflozin4012
Montelukast SodiumMontelukast Sodium4011
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide39suppressed
Escitalopram OxalateEscitalopram Oxalate37suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium36suppressed
XareltoRivaroxaban36suppressed
SynthroidLevothyroxine Sodium34suppressed
DiazepamDiazepam32suppressed
Sumatriptan SuccinateSumatriptan Succinate31suppressed
ValsartanValsartan31suppressed
Trazodone HclTrazodone Hcl30suppressed
Donepezil HclDonepezil Hcl29suppressed
FinasterideFinasteride28suppressed
GabapentinGabapentin28suppressed
Raloxifene HclRaloxifene Hcl28suppressed
Ciprofloxacin HclCiprofloxacin Hcl2722
CarvedilolCarvedilol26suppressed
TelmisartanTelmisartan26suppressed
Citalopram HbrCitalopram Hydrobromide25suppressed
Albuterol Sulfate HfaAlbuterol Sulfate24suppressed
TrulicityDulaglutide24suppressed
RizatriptanRizatriptan Benzoate23suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril22suppressed
Doxazosin MesylateDoxazosin Mesylate22suppressed
LansoprazoleLansoprazole22suppressed
Benazepril HclBenazepril Hcl21suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21suppressed
SpironolactoneSpironolactone21suppressed
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21suppressed
ColchicineColchicine20suppressed
FarxigaDapagliflozin Propanediol20suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide20suppressed
MethylprednisoloneMethylprednisolone2017
Alendronate SodiumAlendronate Sodium19suppressed
ValacyclovirValacyclovir Hcl19suppressed
PrednisonePrednisone18suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl17suppressed
Isosorbide Mononitrate ErIsosorbide Mononitrate17suppressed
PregabalinPregabalin17suppressed
Metformin Hcl ErMetformin Hcl15suppressed
TradjentaLinagliptin14suppressed
Tresiba Flextouch U-200Insulin Degludec14suppressed
Duloxetine HclDuloxetine Hcl13suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl12suppressed
Klor-Con M20Potassium Chloride12suppressed
LorazepamLorazepam12suppressed
Propranolol HclPropranolol Hcl12suppressed
RamiprilRamipril12suppressed
CelecoxibCelecoxib11suppressed
Meclizine HclMeclizine Hcl11suppressed
MounjaroTirzepatide11suppressed
RybelsusSemaglutide11suppressed
VascepaIcosapent Ethyl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $457.73 · 14 records GlaxoSmithKline, LLC. AREXVY, Cologuard Collection Kit, EDARBI, Kerendia, LEQVIO, NEXLETOL, OTEZLA, REPATHA, TRELEGY ELLIPTA, TRINTELLIX — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error